“COST-EFFECTIVENESS ANALYSIS OF ADJUVANT OSIMERTINIB IN RESECTED EGFR-MUTATED EARLY-STAGE NON-SMALL CELL LUNG CANCER IN THAILAND”, ICOPH, vol. 9, no. 1, pp. 45–67, Jan. 2025, doi: 10.17501/24246735.2024.9105.